The Experts below are selected from a list of 48072 Experts worldwide ranked by ideXlab platform

Lin Fritschi - One of the best experts on this subject based on the ideXlab platform.

  • self reported sleep duration sleep quality and Breast Cancer risk in a population based Case control study
    American Journal of Epidemiology, 2013
    Co-Authors: Jennifer Girschik, Jane Heyworth, Lin Fritschi
    Abstract:

    Breast Cancer is one of the most commonly diagnosed invasive Cancers. Established risk factors account for only a small proportion of Cases. Previous studies have found reductions in sleep duration and quality in the general population over time. There is evidence to suggest a link between poor sleep and an increased risk of Breast Cancer. In this study, we investigated the relationship between Breast Cancer and sleep duration and quality in Western Australian women. Data were obtained from a population-based Case-control study conducted from 2009 to 2011. Participants completed a self-administered questionnaire that included questions on sleep. Odds ratios and 95% confidence intervals were calculated using unconditional logistic regression. Sensitivity analysis for potential selection and misclassification bias was also conducted. We found no association between self-reported sleep duration on workdays and risk of Breast Cancer (for 8 hours, OR = 1.10 (95% CI: 0.87, 1.39), compared with the reference category of 7–8 hours’ sleep). In addition, we found no association between sleep duration on nonworkdays, subjective sleep quality, or combined duration and quality and risk of Breast Cancer. This study does not provide evidence to support an association between self-reported sleep duration or quality and the risk of Breast Cancer. Breast Cancer; Case-control studies; circadian rhythm; sleep; sleep duration; sleep quality

Thomas Brüning - One of the best experts on this subject based on the ideXlab platform.

  • Polymorphisms of the nuclear receptor pregnane X receptor and organic anion transporter polypeptides 1A2, 1B1, 1B3, and 2B1 are not associated with Breast Cancer risk
    Breast Cancer Research and Treatment, 2010
    Co-Authors: Christina Justenhoven, Christian Baisch, Volker Harth, Anne Spickenheuer, Sylvia Rabstein, Beate Pesch, Elke Schaeffeler, Stefan Winter, Ute Hamann, Thomas Brüning
    Abstract:

    Organic anion transporter polypeptides (OATPs, s) are involved in the uptake of conjugates steroid hormones such as estrone-3-sulfate. It has been suggested that the expression of OATPs in Breast tissues could impact Breast carcinogenesis and tumor pathology. The nuclear receptor pregnane X receptor (PXR) is involved in the regulation of expression. We investigated 31 variants located in , , , , and for an association with Breast Cancer risk and/or histo-pathological tumor characteristics. Polymorphisms were selected on the basis of a known or potential functional consequence and an allele frequency >2%. Genotyping was performed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry using the GENICA population-based Breast Cancer Case–control collection comprising 1,021 Cases and 1,015 age-matched controls. Statistical analysis was performed by SAS, and all tests were two-sided. None of the 31 analyzed transporter and PXR polymorphisms showed an association with Breast Cancer risk or tumor characteristics. Our data suggest that among the many known transporters common variations of , , , , and do not contribute to Breast carcinogenesis.

  • No evidence for glutathione S-transferases , , , , and in Breast Cancer risk
    Breast Cancer Research and Treatment, 2009
    Co-Authors: Irena E. Andonova, Christian Baisch, Christina Justenhoven, Volker Harth, Anne Spickenheuer, Sylvia Rabstein, Beate Pesch, Stefan Winter, Ute Hamann, Thomas Brüning
    Abstract:

    Breast Cancer is a complex disease and in recent years a number of Breast Cancer susceptibility genes have been identified, but the role of low penetrance susceptibility genes has not been completely resolved. Glutathione S-transferases (GSTs) are phase II xenobiotic metabolizing enzymes involved in the detoxification of chemical carcinogens and environmental pollutants and play an important role in cell defense mechanisms against oxidative stress. They have been in the spot light for the investigation of a potential association with Breast Cancer risk but so far, sparse or even no data for a potential contribution of , , , and to Breast Cancer risk are available. We genotyped _448_C > G (rs2180314), _742_A > C (rs6577), _-832_T > C (rs638820), _-1242_G > A (rs2164624), _419_A > C (rs4925), _-183_A > G (rs2297235), _342_A > G (rs156697), -4378_A > G (rs1046428), and 94_G > A (rs3177427) by MALDI-TOF MS in the German GENICA Breast Cancer Case–control collection of 1021 Cases and 1015 controls and performed Breast Cancer risk association in general and with respect to the stratifications: menopausal status, family history of Breast or ovarian Cancer, use of oral contraceptives, use of hormone therapy, body mass index, and smoking as well as histopathological tumor characteristics including hormone receptor status, grade, histology, and node status. We did not observe any Breast Cancer risk associations and conclude that it is unlikely that glutathione S-transferases GSTA2, GSTM2, GSTO1, GSTO2, and GSTZ1 participate in Breast Cancer susceptibility.

Beate Pesch - One of the best experts on this subject based on the ideXlab platform.

  • No association of polymorphisms in the cell polarity gene with Breast Cancer risk
    Breast Cancer Research and Treatment, 2010
    Co-Authors: Thomas Dünnebier, Klaus Schlaefer, Michael Gilbert, Christian Baisch, Christina Justenhoven, Hiltrud Brauch, Volker Harth, Anne Spickenheuer, Sylvia Rabstein, Beate Pesch
    Abstract:

    The human homolog of the () tumor suppressor gene encodes a protein that regulates apical-basolateral polarity in mammalian epithelia and controls cell proliferation. Due to the role of cell polarity proteins in human Cancers, we investigated whether genetic variability in impacts Breast carcinogenesis and tumor pathology. Five genetic variants were analyzed for an association with Breast Cancer risk and histopathological tumor parameters using a single nucleotide polymorphism (SNP) tagging approach. Genotyping of five tag SNPs was performed by TaqMan allelic discrimination and RFLP-based PCR using the GENICA population-based Breast Cancer Case-control collection including 1,021 Cases and 1,015 age-matched controls. Odds ratios (OR) and 95% confidence intervals (CI) were calculated by ordinal logistic regression. None of the tag SNPs was associated with Breast Cancer risk or tumor characteristics. Our findings suggest that genetic variability in the polarity gene does not contribute to Breast Cancer development.

  • Polymorphisms of the nuclear receptor pregnane X receptor and organic anion transporter polypeptides 1A2, 1B1, 1B3, and 2B1 are not associated with Breast Cancer risk
    Breast Cancer Research and Treatment, 2010
    Co-Authors: Christina Justenhoven, Christian Baisch, Volker Harth, Anne Spickenheuer, Sylvia Rabstein, Beate Pesch, Elke Schaeffeler, Stefan Winter, Ute Hamann, Thomas Brüning
    Abstract:

    Organic anion transporter polypeptides (OATPs, s) are involved in the uptake of conjugates steroid hormones such as estrone-3-sulfate. It has been suggested that the expression of OATPs in Breast tissues could impact Breast carcinogenesis and tumor pathology. The nuclear receptor pregnane X receptor (PXR) is involved in the regulation of expression. We investigated 31 variants located in , , , , and for an association with Breast Cancer risk and/or histo-pathological tumor characteristics. Polymorphisms were selected on the basis of a known or potential functional consequence and an allele frequency >2%. Genotyping was performed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry using the GENICA population-based Breast Cancer Case–control collection comprising 1,021 Cases and 1,015 age-matched controls. Statistical analysis was performed by SAS, and all tests were two-sided. None of the 31 analyzed transporter and PXR polymorphisms showed an association with Breast Cancer risk or tumor characteristics. Our data suggest that among the many known transporters common variations of , , , , and do not contribute to Breast carcinogenesis.

  • No evidence for glutathione S-transferases , , , , and in Breast Cancer risk
    Breast Cancer Research and Treatment, 2009
    Co-Authors: Irena E. Andonova, Christian Baisch, Christina Justenhoven, Volker Harth, Anne Spickenheuer, Sylvia Rabstein, Beate Pesch, Stefan Winter, Ute Hamann, Thomas Brüning
    Abstract:

    Breast Cancer is a complex disease and in recent years a number of Breast Cancer susceptibility genes have been identified, but the role of low penetrance susceptibility genes has not been completely resolved. Glutathione S-transferases (GSTs) are phase II xenobiotic metabolizing enzymes involved in the detoxification of chemical carcinogens and environmental pollutants and play an important role in cell defense mechanisms against oxidative stress. They have been in the spot light for the investigation of a potential association with Breast Cancer risk but so far, sparse or even no data for a potential contribution of , , , and to Breast Cancer risk are available. We genotyped _448_C > G (rs2180314), _742_A > C (rs6577), _-832_T > C (rs638820), _-1242_G > A (rs2164624), _419_A > C (rs4925), _-183_A > G (rs2297235), _342_A > G (rs156697), -4378_A > G (rs1046428), and 94_G > A (rs3177427) by MALDI-TOF MS in the German GENICA Breast Cancer Case–control collection of 1021 Cases and 1015 controls and performed Breast Cancer risk association in general and with respect to the stratifications: menopausal status, family history of Breast or ovarian Cancer, use of oral contraceptives, use of hormone therapy, body mass index, and smoking as well as histopathological tumor characteristics including hormone receptor status, grade, histology, and node status. We did not observe any Breast Cancer risk associations and conclude that it is unlikely that glutathione S-transferases GSTA2, GSTM2, GSTO1, GSTO2, and GSTZ1 participate in Breast Cancer susceptibility.

Jacques Ravel - One of the best experts on this subject based on the ideXlab platform.

  • Investigation of the Association Between the Fecal Microbiota and Breast Cancer in Postmenopausal Women: a Population-Based Case-Control Pilot Study
    JNCI: Journal of the National Cancer Institute, 2015
    Co-Authors: James J. Goedert, Gieira Jones, Guoqin Yu, Roberto Flores, Mitchell H. Gail, Xia Xu, Jianxin Shi, Roni T Falk, Xing Hua, Jacques Ravel
    Abstract:

    We investigated whether the gut microbiota differed in 48 postmenopausal Breast Cancer Case patients, pretreatment, vs 48 control patients. Microbiota profiles in fecal DNA were determined by Illumina sequencing and taxonomy of 16S rRNA genes. Estrogens were quantified in urine. Case-control comparisons employed linear and unconditional logistic regression of microbiota α-diversity (PD_whole tree) and UniFrac analysis of β-diversity, with two-sided statistical tests. Total estrogens correlated with α-diversity in control patients (Spearman Rho = 0.37, P = .009) but not Case patients (Spearman Rho = 0.04, P = .77). Compared with control patients, Case patients had statistically significantly altered microbiota composition (β-diversity, P = .006) and lower α-diversity (P = .004). Adjusted for estrogens and other covariates, odds ratio of Cancer was 0.50 (95% confidence interval = 0.30 to 0.85) per α-diversity tertile. Differences in specific taxa were not statistically significant when adjusted for multiple comparisons. This pilot study shows that postmenopausal women with Breast Cancer have altered composition and estrogen-independent low diversity of their gut microbiota. Whether these affect Breast Cancer risk and prognosis is unknown.

Christina Justenhoven - One of the best experts on this subject based on the ideXlab platform.

  • No association of polymorphisms in the cell polarity gene with Breast Cancer risk
    Breast Cancer Research and Treatment, 2010
    Co-Authors: Thomas Dünnebier, Klaus Schlaefer, Michael Gilbert, Christian Baisch, Christina Justenhoven, Hiltrud Brauch, Volker Harth, Anne Spickenheuer, Sylvia Rabstein, Beate Pesch
    Abstract:

    The human homolog of the () tumor suppressor gene encodes a protein that regulates apical-basolateral polarity in mammalian epithelia and controls cell proliferation. Due to the role of cell polarity proteins in human Cancers, we investigated whether genetic variability in impacts Breast carcinogenesis and tumor pathology. Five genetic variants were analyzed for an association with Breast Cancer risk and histopathological tumor parameters using a single nucleotide polymorphism (SNP) tagging approach. Genotyping of five tag SNPs was performed by TaqMan allelic discrimination and RFLP-based PCR using the GENICA population-based Breast Cancer Case-control collection including 1,021 Cases and 1,015 age-matched controls. Odds ratios (OR) and 95% confidence intervals (CI) were calculated by ordinal logistic regression. None of the tag SNPs was associated with Breast Cancer risk or tumor characteristics. Our findings suggest that genetic variability in the polarity gene does not contribute to Breast Cancer development.

  • Polymorphisms of the nuclear receptor pregnane X receptor and organic anion transporter polypeptides 1A2, 1B1, 1B3, and 2B1 are not associated with Breast Cancer risk
    Breast Cancer Research and Treatment, 2010
    Co-Authors: Christina Justenhoven, Christian Baisch, Volker Harth, Anne Spickenheuer, Sylvia Rabstein, Beate Pesch, Elke Schaeffeler, Stefan Winter, Ute Hamann, Thomas Brüning
    Abstract:

    Organic anion transporter polypeptides (OATPs, s) are involved in the uptake of conjugates steroid hormones such as estrone-3-sulfate. It has been suggested that the expression of OATPs in Breast tissues could impact Breast carcinogenesis and tumor pathology. The nuclear receptor pregnane X receptor (PXR) is involved in the regulation of expression. We investigated 31 variants located in , , , , and for an association with Breast Cancer risk and/or histo-pathological tumor characteristics. Polymorphisms were selected on the basis of a known or potential functional consequence and an allele frequency >2%. Genotyping was performed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry using the GENICA population-based Breast Cancer Case–control collection comprising 1,021 Cases and 1,015 age-matched controls. Statistical analysis was performed by SAS, and all tests were two-sided. None of the 31 analyzed transporter and PXR polymorphisms showed an association with Breast Cancer risk or tumor characteristics. Our data suggest that among the many known transporters common variations of , , , , and do not contribute to Breast carcinogenesis.

  • No evidence for glutathione S-transferases , , , , and in Breast Cancer risk
    Breast Cancer Research and Treatment, 2009
    Co-Authors: Irena E. Andonova, Christian Baisch, Christina Justenhoven, Volker Harth, Anne Spickenheuer, Sylvia Rabstein, Beate Pesch, Stefan Winter, Ute Hamann, Thomas Brüning
    Abstract:

    Breast Cancer is a complex disease and in recent years a number of Breast Cancer susceptibility genes have been identified, but the role of low penetrance susceptibility genes has not been completely resolved. Glutathione S-transferases (GSTs) are phase II xenobiotic metabolizing enzymes involved in the detoxification of chemical carcinogens and environmental pollutants and play an important role in cell defense mechanisms against oxidative stress. They have been in the spot light for the investigation of a potential association with Breast Cancer risk but so far, sparse or even no data for a potential contribution of , , , and to Breast Cancer risk are available. We genotyped _448_C > G (rs2180314), _742_A > C (rs6577), _-832_T > C (rs638820), _-1242_G > A (rs2164624), _419_A > C (rs4925), _-183_A > G (rs2297235), _342_A > G (rs156697), -4378_A > G (rs1046428), and 94_G > A (rs3177427) by MALDI-TOF MS in the German GENICA Breast Cancer Case–control collection of 1021 Cases and 1015 controls and performed Breast Cancer risk association in general and with respect to the stratifications: menopausal status, family history of Breast or ovarian Cancer, use of oral contraceptives, use of hormone therapy, body mass index, and smoking as well as histopathological tumor characteristics including hormone receptor status, grade, histology, and node status. We did not observe any Breast Cancer risk associations and conclude that it is unlikely that glutathione S-transferases GSTA2, GSTM2, GSTO1, GSTO2, and GSTZ1 participate in Breast Cancer susceptibility.